DurVena
Mission, US · Founded 2020 · Delaware corporation
DurVena is developing a photochemical tissue passivation therapy that treats harvested veins to strengthen tissue and improve long-term vein graft durability. The company targets vascular surgery applications where vein grafts are used for reconstructive procedures.
Founders & leadership
ES

Eric SchloteinChief Executive Officer
Board
RT
Robert ThatcherBoard director
WA
William AustenBoard director
Reported raises · per SEC filings
Form D private placements$14M disclosed across 1 round · 2024
▶$14MraisedJan 2025 · 37 investors · Other TechnologyRule 506(b)
▶$14MraisedJan 2025 · 37 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Robert ThatcherDirector
- Eric SchloteExecutive Officer, Director
- William AustenDirector
- Offering amount
- $16.2M
- Amount sold
- $14M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with DurVena for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does DurVena do?
- DurVena is developing a photochemical tissue passivation therapy that treats harvested veins to strengthen tissue and improve long-term vein graft durability. The company targets vascular surgery applications where vein grafts are used for reconstructive procedures.
- How much funding has DurVena raised?
- DurVena has disclosed $14M raised across 1 round.
- Where is DurVena headquartered?
- DurVena is headquartered in Mission, US.

